Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy

 

Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy

Gilead Sciences’ GILD Kite announced encouraging three-year follow-up results from the ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

Tecartus is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is

 approved under accelerated approval based on an overall response rate and durability of the response. The continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Comments

Post a Comment

Popular posts from this blog

The evidence for this is the trotting out of Imagen a month

  The evidence for this is the trotting out of Imagen a month  after DALL-E 2, though like practically every other interesting AI research Google publicized, it was not available for anyone to test out, let alone connect to an API. Then, after Meta released Make-A-Video in September, Google responded with Imagen Video a week later. Riffusion made waves for generating music, and a month later, here comes MusicLM (which you can’t use). But surely it was ChatGPT that caused Google leadership to swiftly transition from anxiety to full-on flop sweat. It would have been clear to all involved that this kind of conversational AI was categorically different from the Assistant products Google had been investing in for a decade, and was actually doing what everyone else’s pseudo-AIs (effectively just natural language frontends for a collection of APIs) pretended to. That’s what’s called an existential threat.
Read more